Invention Grant
- Patent Title: Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors
-
Application No.: US16173100Application Date: 2018-10-29
-
Publication No.: US10555944B2Publication Date: 2020-02-11
- Inventor: Steven W. Andrews , Sean Aronow , James F. Blake , Barbara J. Brandhuber , Adam Cook , Julia Haas , Yutong Jiang , Gabrielle R. Kolakowski , Elizabeth A. McFaddin , Megan L. McKenney , Oren T. McNulty , Andrew T. Metcalf , David A. Moreno , Tony P. Tang , Li Ren
- Applicant: Array BioPharma, Inc.
- Applicant Address: US IN Indianapolis
- Assignee: Eli Lilly and Company
- Current Assignee: Eli Lilly and Company
- Current Assignee Address: US IN Indianapolis
- Agent Michael R. Asam
- Main IPC: C07D401/02
- IPC: C07D401/02 ; C07D401/10 ; A61K31/437 ; A61K31/4353 ; A61K31/496 ; C07D471/04 ; A61P1/12 ; A61P35/04 ; C07D519/00 ; A61P35/02 ; A61P35/00 ; A61K31/444 ; A61K31/4985 ; A61K31/4995 ; A61K31/506 ; A61K31/5377 ; A61K45/06 ; A61K31/551
![Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors](/abs-image/US/2020/02/11/US10555944B2/abs.jpg.150x150.jpg)
Abstract:
Provided herein are compounds of the Formula I: and stereoisomers and pharmaceutically acceptable salts or solvates thereof, in which A, B, X1, X2, X3, X4, Ring D, and E have the meanings given in the specification, which are inhibitors of RET kinase and are useful in the treatment and prevention of diseases which can be treated with a RET kinase inhibitor, including RET-associated diseases and disorders.
Public/Granted literature
- US20190183886A1 SUBSTITUTED PYRAZOLO[1,5-A]PYRIDINE COMPOUNDS AS RET KINASE INHIBITORS Public/Granted day:2019-06-20
Information query